Posted by Michael Wonder on 11 Jun 2018
SMC - June 2018 decisions
11 June 2018 - The SMC, has today published advice accepting six new medicines for use by NHSScotland.
Five of the medicines were accepted through SMC’s Patient and Clinician Engagement (PACE) process, which is used to consider medicines for treating end of life and very rare conditions.
Everolimus (Votubia) was accepted for the treatment of epilepsy in patients with tuberous sclerosis complex (TSC). TSC is a rare genetic disorder affecting both children and adults that causes mainly non-cancerous (benign) tumours to develop in different parts of the body, including the brain.
Inotuzumab ozogamicin (Besponsa) was accepted for the treatment of acute lymphoblastic leukaemia (ALL). The PACE meeting participants reported that ALL is a rare, very aggressive, rapidly progressing form of leukaemia with a particularly poor prognosis and the only possibility of long term survival is a stem cell transplant.
